Compare Stocks: ADVM, RCKT, UPB, and SVA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADVM Adverum Biotechnologies	$4.36	$4.30	$1.78 ▼ $5.75	$96.26M	0.87	452,470 shs	N/A
RCKT Rocket Pharmaceuticals	$3.50 +1.7%	$3.30	$2.53 ▼ $5.45	$375.63M	0.47	1.72 million shs	1.98 million shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$644.66M	0.79	N/A	N/A
UPB Upstream Bio	$6.74 -0.7%	$6.90	$5.85 ▼ $33.68	$369.51M	1.26	521,665 shs	917,141 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADVM Adverum Biotechnologies	0.00%	0.00%	0.00%	0.00%	+73.02%
RCKT Rocket Pharmaceuticals	+1.74%	+11.46%	-12.28%	-4.63%	+15.13%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%
UPB Upstream Bio	-0.74%	+5.15%	-8.92%	-24.94%	-56.52%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADVM Adverum Biotechnologies	$4.36	$4.30	$1.78 ▼ $5.75	$96.26M	0.87	452,470 shs	N/A
RCKT Rocket Pharmaceuticals	$3.50 +1.7%	$3.30	$2.53 ▼ $5.45	$375.63M	0.47	1.72 million shs	1.98 million shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$644.66M	0.79	N/A	N/A
UPB Upstream Bio	$6.74 -0.7%	$6.90	$5.85 ▼ $33.68	$369.51M	1.26	521,665 shs	917,141 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADVM Adverum Biotechnologies	0.00%	0.00%	0.00%	0.00%	+73.02%
RCKT Rocket Pharmaceuticals	+1.74%	+11.46%	-12.28%	-4.63%	+15.13%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%
UPB Upstream Bio	-0.74%	+5.15%	-8.92%	-24.94%	-56.52%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADVM Adverum Biotechnologies	1.80	Reduce	$10.50	140.83% Upside
RCKT Rocket Pharmaceuticals	2.30	Hold	$8.71	148.98% Upside
SVA Sinovac Biotech	0.00	N/A	N/A	N/A
UPB Upstream Bio	2.43	Hold	$33.17	392.09% Upside

Current Analyst Ratings Breakdown

Latest ADVM, RCKT, UPB, and SVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/3/2026	UPB Upstream Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/15/2026	RCKT Rocket Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/29/2026	RCKT Rocket Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/12/2026	UPB Upstream Bio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$35.00 ➝ $8.00
6/3/2026	UPB Upstream Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$36.00
6/3/2026	UPB Upstream Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$36.00
6/1/2026	RCKT Rocket Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/14/2026	RCKT Rocket Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/14/2026	UPB Upstream Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$51.00 ➝ $50.00
5/11/2026	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$11.00
5/6/2026	UPB Upstream Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	$3.40 per share	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$2.56 per share	N/A
SVA Sinovac Biotech	$386.01M	1.67	$0.54 per share	11.89	$89.01 per share	0.07
UPB Upstream Bio	$2.85M	128.70	N/A	N/A	$6.29 per share	1.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADVM Adverum Biotechnologies	-$130.93M	-$8.58	N/A	N/A	N/A	N/A	-3,476.17%	-152.07%	N/A
RCKT Rocket Pharmaceuticals	-$223.12M	-$1.87	N/A	N/A	N/A	N/A	-69.61%	-58.63%	8/6/2026 (Estimated)
SVA Sinovac Biotech	-$59.68M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	8/13/2026 (Estimated)
UPB Upstream Bio	-$143.44M	-$2.91	N/A	N/A	N/A	-4,718.96%	-43.82%	-42.27%	N/A

Latest ADVM, RCKT, UPB, and SVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	RCKT Rocket Pharmaceuticals	$0.86	N/A	N/A	N/A	$0.22 million	N/A
5/13/2026	Q1 2026	UPB Upstream Bio	-$0.73	-$0.7470	-$0.0170	-$0.75	$1.03 million	$1.03 million
5/7/2026	Q1 2026	RCKT Rocket Pharmaceuticals	-$0.41	-$0.42	-$0.01	-$0.42	$4.47 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SVA Sinovac Biotech	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADVM Adverum Biotechnologies	N/A	0.65	0.65
RCKT Rocket Pharmaceuticals	0.08	6.12	6.12
SVA Sinovac Biotech	0.04	4.59	4.53
UPB Upstream Bio	N/A	23.14	23.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADVM Adverum Biotechnologies	48.17%
RCKT Rocket Pharmaceuticals	98.39%
SVA Sinovac Biotech	N/A
UPB Upstream Bio	N/A

Insider Ownership

Company	Insider Ownership
ADVM Adverum Biotechnologies	6.00%
RCKT Rocket Pharmaceuticals	21.30%
SVA Sinovac Biotech	12.79%
UPB Upstream Bio	16.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADVM Adverum Biotechnologies	190	22.08 million	20.75 million	Optionable
RCKT Rocket Pharmaceuticals	240	109.19 million	85.94 million	Optionable
SVA Sinovac Biotech	3,008	99.64 million	86.89 million	Optionable
UPB Upstream Bio	38	54.42 million	45.46 million	N/A

ADVM, RCKT, UPB, and SVA Headlines

Recent News About These Companies

Arrowstreet Capital Limited Partnership Buys New Holdings in Upstream Bio, Inc. $UPB

1 hour ago | marketbeat.com

Analysts Set Upstream Bio, Inc. (NASDAQ:UPB) PT at $33.17

August 5 at 2:28 AM | americanbankingnews.com

Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of "Hold" from Analysts

July 31, 2026 | marketbeat.com

Upstream Bio (UPB) Expected to Release Quarterly Earnings on Wednesday

July 29, 2026 | marketbeat.com

Altshuler Shaham Ltd Reduces Position in Upstream Bio, Inc. $UPB

July 29, 2026 | marketbeat.com

Hsbc Holdings PLC Makes New $5.76 Million Investment in Upstream Bio, Inc. $UPB

July 24, 2026 | marketbeat.com

Decheng Capital LLC Sells 418,210 Shares of Upstream Bio, Inc. $UPB

July 23, 2026 | marketbeat.com

SEB Asset Management AB Buys New Stake in Upstream Bio, Inc. $UPB

July 22, 2026 | marketbeat.com

Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?

July 14, 2026 | zacks.com

Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?

June 25, 2026 | insidermonkey.com

10 small-cap U.S. healthcare stocks with the weakest momentum grades

June 24, 2026 | seekingalpha.com

Is Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026?

June 23, 2026 | insidermonkey.com

Upstream Bio Initiates a Phase 2 Clinical Trial of Verekitug (UPB-101) in Severe Asthma and Doses First Patients

June 19, 2026 | businesswire.com

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the ...

June 14, 2026 | markets.businessinsider.com

Upstream Bio Reports Positive Phase 2 Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps, Achieving Clinically Meaningful Improvements in Key Symptoms

June 14, 2026 | quiverquant.comQ

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

June 14, 2026 | globenewswire.com

KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust

June 12, 2026 | businesswire.com

Upstream Bio Launches $150 Million At-The-Market Program

June 11, 2026 | theglobeandmail.com

Upstream Bio Shareholders Elect Directors, Ratify 2026 Auditor

June 10, 2026 | tipranks.com

Upstream Bio, Inc. (UPB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 10, 2026 | seekingalpha.com

Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug ...

June 8, 2026 | enidnews.comE

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADVM, RCKT, UPB, and SVA Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Rocket Pharmaceuticals NASDAQ:RCKT

$3.50 +0.06 (+1.74%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$3.53 +0.03 (+0.80%)

As of 04:11 AM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Sinovac Biotech NASDAQ:SVA

$6.47 0.00 (0.00%)

As of 08/4/2026

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

Upstream Bio NASDAQ:UPB

$6.74 -0.05 (-0.74%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$6.65 -0.09 (-1.34%)

As of 04:00 AM Eastern

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADVM, RCKT, UPB, and SVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADVM, RCKT, UPB, and SVA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADVM, RCKT, UPB, and SVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADVM, RCKT, UPB, and SVA Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

Rocket Pharmaceuticals NASDAQ:RCKT

Sinovac Biotech NASDAQ:SVA

Upstream Bio NASDAQ:UPB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADVM, RCKT, UPB, and SVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADVM, RCKT, UPB, and SVA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADVM, RCKT, UPB, and SVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADVM, RCKT, UPB, and SVA Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

Rocket Pharmaceuticals NASDAQ:RCKT

Sinovac Biotech NASDAQ:SVA

Upstream Bio NASDAQ:UPB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools